George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Now we know why Avacta said they will be financially well placed to continue funding AVA6000 trial...
More global traction for affimer technology...all good...
Agreed, report and ignore the goons
Bump to ignore TW’s crew.
Okay, all well and good but still no mention of the LFT :-))
(Okay, I admit it. I've just ripped-off Timster's joke from yesterday)
Can't think of too many better weeks on this board.
WOW JUST WOW!
the share that keeps on giving..
This share price would be touching £3+ last year.. Market is fooked at present its like ebenezer scrooge is at the helm!
LG spend their $$ on R&D and pay Avacta for their IP
Must be looking good their end in the Lab
AS WHY RAMPNG, WHY!!!
What a brilliant company to be a shareholder of
MrA…..these days 2 million USD is nearly the same as 2 million GBP……
Seems a smart move that Avacta have these partnership deals established in USD currency.
Was it 4 million last year now 2 million love it
Lovely little bonus there. I wonder why they renewed eh? Must be crap. Hahahaha.
$2m bonus but lets keep focus on the bigger picture, which is that this deal is progressing towards clinic and could be worth $1b to Avata:
https://www.businessweekly.co.uk/news/biomedtech/thanks-billion-lg-chem-broadens-deal-avacta
Avacta Group could earn anything from $1/2bn to $1bn from an extended partnership with LG Chem Life Science, the Massachusetts-based subsidiary of the South Korean LG Group.
The windfall stems from additional drug development programmes utilising Avacta’s Affimer® XT technology.
The foundations were laid in December 2018 when the companies agreed to develop Affimer® therapeutics in several disease areas potentially worth over $300m to Avacta.
Now the drug development partnership is being extended to include Avacta’s Affimer XTTM technology, which can be used to control the time a drug spends in the circulation.
The expansion of the partnership includes an undisclosed additional upfront payment, plus near-term pre-clinical milestones and longer-term clinical development milestones totalling $98.5m for two therapeutics to be developed using the Affimer XT technology.
LG Chem has the exclusive rights to develop and commercialise, on a world-wide basis, Avacta’s Affimer PD-L1 inhibitor with Affimer XT serum half-life extension.
The new deal also provides LG Chem with rights to develop and commercialise other Affimer and non-Affimer biotherapeutics combined with Affimer XT half-life extension for a range of indications and Avacta could earn up to $55m in milestone payments for each of these new products.
Avacta, which has operations in Cambridge and Wetherby, will also earn royalties on all future Affimer XT product sales by LG Chem.
Chief executive Dr Alastair Smith said: “LG Chem is a world-class drug development partner with excellent biologics manufacturing and clinical development capabilities and a pioneering vision to develop innovative therapies.
“The expansion of our collaboration to develop new therapies for patients with cancer and other diseases is another strong validation of the Affimer technology and its potential as a therapeutic platform to deliver a pipeline of new drugs.”
What a great £2,000,000 bonus this morning! Well done Avacta
He said inflection points and start Q3 Friday … Excellent news … Point next ? Affyxell next ?
BOOOOM